Literature DB >> 15520175

Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3.

Munenori Takaoka1, Hideki Harada, Claudia D Andl, Kenji Oyama, Yoshio Naomoto, Kelly L Dempsey, Andres J Klein-Szanto, Wafik S El-Deiry, Adda Grimberg, Hiroshi Nakagawa.   

Abstract

Epidermal growth factor receptor (EGFR) is frequently overexpressed in esophageal carcinoma and its precursor lesions. To gain insights into how EGFR overexpression affects cellular functions in primary human esophageal cells, we performed gene expression profiling and identified insulin-like growth factor-binding protein (IGFBP)-3 as the most up-regulated gene. IGFBP-3 regulates cell proliferation through both insulin-like growth factor-dependent and independent mechanisms. We found that IGFBP-3 mRNA and protein expression was increased in EGFR-overexpressing primary and immortalized human esophageal cells. IGFBP-3 was also up-regulated in EGFR-overexpressing cells in organotypic culture and in EGFR transgenic mice. Furthermore, IGFBP-3 mRNA was overexpressed in 80% of primary esophageal squamous cell carcinomas and 60% of primary esophageal adenocarcinomas. Concomitant up-regulation of EGFR and IGFBP-3 was observed in 60% of primary esophageal squamous cell carcinomas. Immunohistochemistry revealed cytoplasmic localization of IGFBP-3 in the preponderance of preneoplastic and neoplastic esophageal lesions. IGFBP-3 was also overexpressed in esophageal cancer cell lines at both mRNA (60%) and protein (40%) levels. IGFBP-3 secreted by cancer cells was capable of binding to insulin-like growth factor I. Functionally, epidermal growth factor appeared to regulate IGFBP-3 expression in esophageal cancer cell lines. Finally, suppression of IGFBP-3 by small interfering RNA augmented cell proliferation, suggesting that IGFBP-3 may inhibit tumor cell proliferation as a negative feedback mechanism. In aggregate, we have identified for the first time that IGFBP-3 is an aberrantly regulated gene through the EGFR signaling pathway and it may modulate EGFR effects during carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15520175      PMCID: PMC4140096          DOI: 10.1158/0008-5472.CAN-04-0715

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  59 in total

1.  Telomerase induces immortalization of human esophageal keratinocytes without p16INK4a inactivation.

Authors:  Hideki Harada; Hiroshi Nakagawa; Kenji Oyama; Munenori Takaoka; Claudia D Andl; Birgit Jacobmeier; Alexander von Werder; Gregory H Enders; Oliver G Opitz; Anil K Rustgi
Journal:  Mol Cancer Res       Date:  2003-08       Impact factor: 5.852

2.  Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation.

Authors:  J Okano; I Gaslightwala; M J Birnbaum; A K Rustgi; H Nakagawa
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

3.  Isolation and characterization of proteolytic fragments of insulin-like growth factor-binding protein-3.

Authors:  C Lalou; C Lassarre; M Binoux
Journal:  Horm Res       Date:  1996

4.  Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo.

Authors:  Claudia D Andl; Takaaki Mizushima; Hiroshi Nakagawa; Kenji Oyama; Hideki Harada; Katerina Chruma; Meenhard Herlyn; Anil K Rustgi
Journal:  J Biol Chem       Date:  2002-11-14       Impact factor: 5.157

5.  Expression of insulin-like growth factor binding protein-3 (IGFBP-3) in human keratinocytes is regulated by EGF and TGFbeta1.

Authors:  S R Edmondson; M M Murashita; V C Russo; C J Wraight; G A Werther
Journal:  J Cell Physiol       Date:  1999-05       Impact factor: 6.384

6.  Detection of multiple gene hypermethylation in the development of esophageal squamous cell carcinoma.

Authors:  Yan Nie; Jie Liao; Xin Zhao; Yunlong Song; Guang-yu Yang; Li-Dong Wang; Chung S Yang
Journal:  Carcinogenesis       Date:  2002-10       Impact factor: 4.944

7.  Expression of the insulin like growth factor-binding protein 3 (IGFBP-3) gene is increased in human renal carcinomas.

Authors:  R L Hintz; S Bock; A V Thorsson; J Bovens; D R Powell; G Jakse; P E Petrides
Journal:  J Urol       Date:  1991-10       Impact factor: 7.450

8.  The expression of insulin-like growth factor binding proteins in human hepatocellular carcinoma.

Authors:  Y Gong; L Cui; G Y Minuk
Journal:  Mol Cell Biochem       Date:  2000-04       Impact factor: 3.396

9.  Insulin-like growth factor-binding protein 3 expression increases during immortalization of cervical keratinocytes by human papillomavirus type 16 E6 and E7 proteins.

Authors:  Allison J Berger; Astrid Baege; Tracy Guillemette; James Deeds; Ron Meyer; Gary Disbrow; Richard Schlegel; Robert Schlegel
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

10.  Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification.

Authors:  Y Itakura; H Sasano; C Shiga; Y Furukawa; K Shiga; S Mori; H Nagura
Journal:  Cancer       Date:  1994-08-01       Impact factor: 6.860

View more
  42 in total

1.  Low expression of IGFBP-3 predicts poor prognosis in patients with esophageal squamous cell carcinoma.

Authors:  Lei Zhao; Li-Ru He; Rui Zhang; Mu-Yan Cai; Yi-Ji Liao; Dong Qian; Mian Xi; Yi-Xin Zeng; Dan Xie; Meng-Zhong Liu
Journal:  Med Oncol       Date:  2011-12-14       Impact factor: 3.064

2.  Association of insulin and insulin-like growth factors with Barrett's oesophagus.

Authors:  Katarina B Greer; Cheryl L Thompson; Lacie Brenner; Beth Bednarchik; Dawn Dawson; Joseph Willis; William M Grady; Gary W Falk; Gregory S Cooper; Li Li; Amitabh Chak
Journal:  Gut       Date:  2011-09-19       Impact factor: 23.059

3.  Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors.

Authors:  Shinya Ohashi; Mitsuteru Natsuizaka; Gabrielle S Wong; Carmen Z Michaylira; Katharine D Grugan; Douglas B Stairs; Jiri Kalabis; Maria E Vega; Ross A Kalman; Momo Nakagawa; Andres J Klein-Szanto; Meenhard Herlyn; J Alan Diehl; Anil K Rustgi; Hiroshi Nakagawa
Journal:  Cancer Res       Date:  2010-04-27       Impact factor: 12.701

4.  The effect of IGF-I receptor blockade for human esophageal squamous cell carcinoma and adenocarcinoma.

Authors:  Yasushi Adachi; Hirokazu Ohashi; Arisa Imsumran; Hiroyuki Yamamoto; Yasutaka Matsunaga; Hiroaki Taniguchi; Katsuhiko Nosho; Hiromu Suzuki; Yasushi Sasaki; Yoshiaki Arimura; David P Carbone; Kohzoh Imai; Yasuhisa Shinomura
Journal:  Tumour Biol       Date:  2013-09-13

Review 5.  Cancer.

Authors:  Adda Grimberg
Journal:  Adv Exp Med Biol       Date:  2005       Impact factor: 2.622

6.  Identification of a novel cell death receptor mediating IGFBP-3-induced anti-tumor effects in breast and prostate cancer.

Authors:  Angela R Ingermann; Yong-Feng Yang; Jinfeng Han; Aki Mikami; Amanda E Garza; Lathika Mohanraj; Lingbo Fan; Michael Idowu; Joy L Ware; Ho-Seong Kim; Dae-Yeol Lee; Youngman Oh
Journal:  J Biol Chem       Date:  2010-03-30       Impact factor: 5.157

7.  Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.

Authors:  Marta Guix; Anthony C Faber; Shizhen Emily Wang; Maria Graciela Olivares; Youngchul Song; Sherman Qu; Cammie Rinehart; Brenda Seidel; Douglas Yee; Carlos L Arteaga; Jeffrey A Engelman
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

8.  Interplay between microRNA-17-5p, insulin-like growth factor-II through binding protein-3 in hepatocellular carcinoma.

Authors:  Danira Ashraf Habashy; Hend Mohamed El Tayebi; Injie Omar Fawzy; Karim Adel Hosny; Gamal Esmat; Ahmed Ihab Abdelaziz
Journal:  World J Hepatol       Date:  2016-08-18

9.  Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept.

Authors:  Tomislav Dragovich; Christopher Campen
Journal:  J Oncol       Date:  2009-07-14       Impact factor: 4.375

10.  Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro.

Authors:  Jheri J Dupart; Jonathan C Trent; Ho-Young Lee; Kenneth R Hess; Andrew K Godwin; Takahiro Taguchi; Wei Zhang
Journal:  Mol Cancer       Date:  2009-11-10       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.